---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-021116"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:10:46.139574+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical regains compliance with Nasdaq listing requirement after MVLS deficiency

## Summary
- Received Nasdaq letter confirming compliance with Listing Rule 5550(b)(2) after MVLS fell below $35M.
- Discretionary panel monitor imposed for one year from February 12, 2026.
- Company implemented strategic financing initiatives to strengthen balance sheet and regain compliance.
- Original non-compliance notice received February 25, 2025; now resolved.

## SEC filing metadata
- accession: 0001213900-26-021116
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390026021116/0001213900-26-021116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390026021116/envoy-8k_022326.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-021116
- JSON: https://secwatch.observer/filing/0001213900-26-021116.json
- Plain text: https://secwatch.observer/filing/0001213900-26-021116.txt

## Source-grounded claims
- claim_id: c8b6d831c302ceb5fd84fb338b17ffd5d2c6c563
  claim: Envoy Medical, Inc. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(2), 5815(d)(4)(B)).
  evidence_excerpt: February 23, 2026, Envoy Medical, Inc. (the “Company”) received a letter from the Nasdaq Listing Qualifications Hearings office confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) in compliance with the Nasdaq Hearing Panel’s letter dated October 23, 2025. In addition, pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a discretionary panel monitor for a period of one year from February 12, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840877/000121390026021116/0001213900-26-021116-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.